Compare Twilio Inc (TWLO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twilio Inc vs Twist Bioscience Corp — how do they compare? Twilio Inc trades at $247.06 (market cap $39.31B), while Twist Bioscience Corp trades at $125.99 (market cap $7.72B). The key difference: Twilio Inc is far larger — about 5.1× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| TWLO | TWST | |
|---|---|---|
Market Cap | $39.31B | $7.72B |
Sector | Technology | Health |
52-Week High | $255.95 | $124.88 |
52-Week Low | $95.23 | $24.16 |
Enterprise Value | $37.72B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $247.64, down 0.97% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $1.47 actual vs. $1.32 expected, and raised full-year revenue growth guidance to 18-18.5%. Fundamentals show improving profitability, with net income margin reaching 20.62% in 2026, and positive cash flow trends.
The outlook is positive due to accelerating revenue growth and robust free cash flow generation, but risks include high valuation multiples like a P/E of 35.35 and competitive pressures in cloud communications. Analyst consensus is strongly bullish with a $266.31 price target, suggesting potential upside from current levels.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
